CA 125 REGRESSION - A MODEL FOR EPITHELIAL OVARIAN-CANCER RESPONSE

被引:46
作者
BULLER, RE
BERMAN, ML
BLOSS, JD
MANETTA, A
DISAIA, PJ
机构
[1] UNIV CALIF IRVINE,DEPT GYNECOL,DIV GYNECOL ONCOL,IRVINE,CA 92717
[2] UNIV IOWA,MED CTR,IOWA CITY,IA 52242
[3] UNIV CALIF IRVINE,DEPT OBSTET,DIV GYNECOL ONCOL,IRVINE,CA 92717
关键词
CA; 125; EXPONENTIAL REGRESSION; CHEMOTHERAPY;
D O I
10.1016/0002-9378(91)90093-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The rate of decline of CA 125 in effectively treated epithelial ovarian cancer is described by the exponential regression curve CA 125 = EXP [i - s (days after surgery)]. In this equation i, the y-axis intercept, measures initial tumor burden whereas s, the slope of the regression curve, is determined by the extent of cytoreductive surgery and the subsequent response to chemotherapy. Departure from the regression curve uniformly results in progressive disease. In patients whose cancers had been completely removed, we calculated the mean half-life of CA 125 to be 10.4 days (range 4 to 21). In this case s = 0.0835 and characterizes the ideal regression rate. The model predicts that high-dose cisplatin chemotherapy (s = 0.0671) is more effective than low-dose cisplatin (s = 0.0380) (p < 0.03) in eliminating residual cancer. Because s can be calculated within 2 to 3 months of treatment and then compared with s for the ideal regression curve and with the values of s reported for standard chemotherapy, evaluation of any new treatment protocol can be facilitated with this method.
引用
收藏
页码:360 / 367
页数:8
相关论文
共 25 条
  • [1] A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER
    BAST, RC
    KLUG, TL
    STJOHN, E
    JENISON, E
    NILOFF, JM
    LAZARUS, H
    BERKOWITZ, RS
    LEAVITT, T
    GRIFFITHS, CT
    PARKER, L
    ZURAWSKI, VR
    KNAPP, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) : 883 - 887
  • [2] HIGH-DOSE PLATINUM FOR THE TREATMENT OF REFRACTORY OVARIAN-CANCER
    BRUCKNER, HW
    WALLACH, R
    COHEN, CJ
    DEPPE, G
    KABAKOW, B
    RATNER, L
    HOLLAND, JF
    [J]. GYNECOLOGIC ONCOLOGY, 1981, 12 (01) : 64 - 67
  • [3] DOES INTRAPERITONEAL CA-125 REFLECT DISEASE STATUS
    BULLER, RE
    MANETTA, A
    BLOSS, JD
    DISAIA, PJ
    BERMAN, ML
    [J]. GYNECOLOGIC ONCOLOGY, 1991, 40 (01) : 66 - 69
  • [4] OVARIAN-CANCER ANTIGEN CA125 - A PROSPECTIVE CLINICAL-ASSESSMENT OF ITS ROLE AS A TUMOR-MARKER
    CANNEY, PA
    MOORE, M
    WILKINSON, PM
    JAMES, RD
    [J]. BRITISH JOURNAL OF CANCER, 1984, 50 (06) : 765 - 769
  • [5] DISAIA PJ, 1989, CLIN GYNECOLOGIC ONC, P325
  • [6] GOODMAN LS, 1985, PHARMACOL BASIS THER, P40
  • [7] HACKER NF, 1983, OBSTET GYNECOL, V61, P413
  • [8] CYTOREDUCTIVE SURGERY IN OVARIAN-CARCINOMA - FEASIBILITY AND MORBIDITY
    HEINTZ, APM
    HACKER, NF
    BEREK, JS
    ROSE, TP
    MUNOZ, AK
    LAGASSE, LD
    [J]. OBSTETRICS AND GYNECOLOGY, 1986, 67 (06) : 783 - 788
  • [9] KIVINEN S, 1986, OBSTET GYNECOL, V67, P468
  • [10] LAVIN PT, 1987, OBSTET GYNECOL, V69, P223